

Suiseng Diff/A (--) - Suspension for injection

Authorised

- Clostridium difficile toxoid A
- Clostridium difficile toxoid B
- Clostridium perfringens, type A, alpha toxoid

Product identification

Medicine name:

Suiseng Diff/A (--) - Suspension for injection

Active substance:

Clostridium difficile toxoid A

Clostridium difficile toxoid B

Clostridium perfringens, type A, alpha toxoid

Target species:

Pig

Route of administration:

Intramuscular use

Product details

Active substance and strength:

Clostridium difficile toxoid A

Presentation_strength:RP $\geq$ 1.60 Reference:Hse Index:0

Clostridium difficile toxoid B

Presentation_strength:RP $\geq$ 1.65 Reference:Hse Index:1

Clostridium perfringens, type A, alpha toxoid

Presentation_strength:RP $\geq$ 1.34 Reference:Hse Index:2

Pharmaceutical form:

Suspension for injection

Withdrawal period by route of administration:

Intramuscular use:

-

Pig

- Not applicable. 0 day Zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI09AB12

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:

Packaging:Vial (PET), Package_size:1 vial, Content:250 ml (50 doses)

Packaging:Vial (PET), Package_size:1 vial, Content:100 ml (50 doses)

Packaging:Vial (PET), Package_size:1 vial, Content:100 ml (25 doses)

Packaging:Vial (PET), Package_size:1 vial, Content:50 ml (25 doses)

Packaging:Vial (PET), Package_size:1 vial, Content:50 ml (10 doses)

Packaging:Vial (PET), Package_size:1 vial, Content:20 ml (10 doses)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Laboratorios Hipra, S.A.

Marketing authorisation date:

7/12/2021

Manufacturing sites for batch release:

Laboratorios Hipra S.A.

Responsible authority:

European Commission

Authorisation number:

This information is not available for this product.

Date of authorisation status change:

7/12/2021

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 16/06/2025

Download

ema-puar-suiseng-diff-a-v-5596-par-en.pdf